J&J Moves to Redefine Cancer Treatment Through Halda Therapeutics Buyout
Johnson & Johnson Strengthens Oncology Leadership With $3.05 Billion Acquisition of Halda Therapeutics and Its Next-Generation RIPTAC™ Platform Johnson & Johnson (NYSE: JNJ) announced that it has entered into a…
JSR Life Sciences Reaches Definitive Agreement to Transfer Crown Bioscience to Adicon
JSR Life Sciences Announces Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings, Marking a Significant Strategic Realignment in Oncology Research Services JSR Life Sciences LLC (“JSR Life Sciences”), a…
Inflammasome Therapeutics, Healey & AMG Center Launch ALS Treatment Collaboration
Inflammasome Therapeutics to Collaborate with Healey & AMG Center on New ALS Treatment Study Inflammasome Therapeutics, a clinical-stage biotechnology company advancing a new category of drug candidates known as Kamuvudines…
Flightpath Biosciences Boosts Pipeline with New Drug License, Launches New Brand Identity
Flightpath Biosciences Advances Precision Anti-Infective Strategy with New Drug License and Corporate Rebrand as Company Enters Next Phase of Growth Flightpath Biosciences, a clinical-stage biotechnology company committed to developing innovative…
Survey Finds Non–Muscle Invasive Bladder Cancer Patients Want More Dialogue in Their Care
New Survey Shows NMIBC Patients Want More Inclusive Care Conversations and Greater Awareness of Emerging Treatment Options A new national survey conducted in the United States by The Harris Poll,…
Gilead’s Bictegravir–Lenacapavir HIV Pill Meets Phase 3 ARTISTRY-1 Goal
Single-tablet regimen shows non-inferior efficacy and strong safety in virologically suppressed adults with HIV-1. Gilead Sciences, Inc. (NASDAQ: GILD) has announced encouraging topline results from its Phase 3 ARTISTRY-1 clinical…
KORU Medical Systems Reports 27% Revenue Growth in Q3 and Increases Full-Year 2025 Outlook
KORU Medical Systems Reports 27% Third Quarter Revenue Growth and Raises Full-Year 2025 Guidance KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology firm…
AN2 Therapeutics Announces Q3 2025 Financial Results and Key Corporate & Scientific Updates
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business and Scientific Updates AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing novel small-molecule therapeutics…
Kezar Life Sciences Announces Q3 2025 Financial Results
Kezar Life Sciences Provides Third Quarter 2025 Financial and Corporate Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics targeting immune-mediated diseases, announced…
Deciphera to Showcase New Clinical Data at the 2025 CTOS Annual Meeting
Deciphera to Present Comprehensive Pipeline Data at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and…
Dyno Therapeutics, Trisk Bio Form Strategic Manufacturing Partnership
Dyno Therapeutics and Trisk Bio Forge Strategic Manufacturing Alliance to Advance Genetic Agency through Expanded Frontiers Program Dyno Therapeutics, Inc., a genetic technologies company leveraging artificial intelligence (AI) to revolutionize…
Ionis Pharmaceuticals Announces New Convertible Offering for 2026 Note Refinancing
Ionis Pharmaceuticals Announces $700 Million Convertible Senior Notes Offering to Refinance 2026 Debt and Strengthen Long-Term Financial Flexibility Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a leading biopharmaceutical company advancing RNA-targeted therapeutics,…